Hypofractionation in locally advanced NSCLC: outcome, toxicity and predictive factors

被引：0
|
作者：
Franceschini, D. [1 ]
Marzo, A. [1 ,2 ]
Lo Faro, L. [1 ,2 ]
Marini, B. [1 ,2 ]
Di Cristina, L. [1 ,3 ]
Franzese, C. [1 ,3 ]
Galdieri, C. [1 ]
Massaro, M. [1 ]
Spoto, R. [1 ]
Dominici, L. [1 ]
Scorsetti, M. [1 ,2 ]
机构：
[1] IRCCS Humanitas Res Hosp, Radiotherapy & Radiosurg, Milan, Italy
[2] Humanitas Univ, Biomed Sci, Pieve Emanuele Milan, Italy
[3] Humanitas Univ, Biomed Sci, Milan, Italy
来源：
RADIOTHERAPY AND ONCOLOGY | 2022年 / 170卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-1281
引用
下载
收藏
页码：S1080 / S1080
页数：1
相关论文
共 50 条
  • [21] Is skin toxicity a predictive or prognostic factor in EGFR-inhibition as treatment of advanced NSCLC?
    Ruediger, Stefan
    Kropf-Sanchen, Cornelia
    Schmid-Bindert, Gerald
    Wibmer, Thomas
    Stoiber, Kathrin
    Blanta, Ioanna
    Rottbauer, Wolfgang
    Schumann, Christian
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [22] Multivariable predictive modeling of acute esophageal toxicity after IMRT for advanced stage NSCLC
    Wijsman, R.
    Dankers, F.
    Troost, E. G. C.
    Hoffmann, A. L.
    Bussink, J.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S322 - S322
  • [23] Low esophageal toxicity during simultaneous modulated accelerated radiotherapy (SMART) in locally advanced NSCLC
    Chajon, E.
    Bellec, J.
    Castelli, J.
    Kerjouan, M.
    Corre, R.
    Lena, H.
    Molina, S.
    Le Prise, E.
    De Crevoisier, R.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S39 - S39
  • [24] Reducing radiotherapy dose to involved lymph nodes in locally advanced NSCLC: efficacy and toxicity.
    Van Diessen, J.
    Kwint, M.
    Sonke, J.
    Walraven, I.
    Stam, B.
    De Langen, J.
    Belderbos, J.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S27 - S28
  • [25] Preoperative treatment with cisplatin-gemcitabine in locally advanced nsclc:: Survival, toxicity and salvage surgery
    Rubio, I
    López-Vivanco, G
    Barceló, J
    Muñoz, A
    Mañé, J
    Fernández, R
    Abón, G
    Fuente, N
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [26] How many locally advanced NSCLC patients receive Durvalumab and what are the limiting factors?
    Sharma, Catherine
    Pascoe, Abigail
    LUNG CANCER, 2024, 190
  • [27] How many locally advanced NSCLC patients receive Durvalumab and what are the limiting factors?
    Sharma, Catherine
    Pascoe, Abigail
    LUNG CANCER, 2024, 190
  • [28] Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
    Gao, G.
    Cheng, L.
    Zhao, C.
    Li, X.
    Yao, C.
    Li, F.
    You, D.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S353 - S354
  • [29] Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
    Evers, G.
    Reitnauer, L. E.
    Christoph, D. C. C.
    Brueckl, W. M.
    Wiesweg, M.
    Glanemann, F.
    Webendoerfer, M.
    Kropf, C.
    Acker, F.
    Hund, A-C.
    Schuette, W.
    Hoffknecht, P.
    Kerkhoff, A.
    Mohr, M.
    Lenz, G.
    Frost, N.
    Overbeck, T. R.
    Sebastian, M.
    Bleckmann, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S749 - S749
  • [30] Bimodality or trimodality treatment in locally advanced NSCLC
    Wagner, Wolfgang
    LUNG CANCER, 2012, 77 : S18 - S18
12345